The North America peptide therapeutics market size accounted for USD 87.36 billion in 2025 and is predicted to touch around USD 185.14 billion by 2035, growing at a CAGR of 7.8% from 2026 to 2035. The robust biotech R&D, mainly focused on cancer supportive care, is driving growth in the oncology sector. While the back-to-back FDA approvals due to growing rare disease conditions are strengthening the base of the market.

North America Peptide Therapeutics Market Statical Scope

The strong foundation of manufacturing and AI due to heavy adoption of advancements is an improvement to SPPS. Whereas CDMO's manufacturing potential is a boon to the production line. The alliances between the biotech and pharmaceutical industries are concentrating on metabolic conditions for more solutions and profit to the market.

North America Peptide Therapeutics Market Share, By Type Outlook, 2025 (%)

• Innovative -The innovative segment acquired 72% of the share in 2025, with the expected satisfying growth in the future, with the rising specialization and advancements in the oncology and metabolic space. This stimulates the demand for effective GLP-1 peptides as peptide therapies are a part of oncology in line with the personalized medicine trend.
• Generic - The generic segment held 28% of the share in 2025, with steady growth in the coming years due to the rising number of metabolic conditions. The peptide synthesis technologies are supporting the manufacturing of generic alternatives, promoting tech-driven approaches in the segmental market.

North America Peptide Therapeutics Market Share, By Application Outlook, 2025 (%)

• Cancer -The cancer segment confirmed 29% of the share in 2025, with the smart growth in the near future, with the grace of tech advancements featuring the performance of peptide-drug conjugates and stapled peptides. The healthcare champions are contributing to the advances of cancer-based peptide drugs.
• Metabolic Disorders -The metabolic disorders segment held 18% of the share in 2025, with the commendable growth strategy of focusing on modern peptide formulations. The growing number of people with diabetes in Canada and the U.S. is demanding more accessibility to effective solutions supporting advanced treatments for the same.
• Neurological Disorders - The neurological disorders segment acquired 12% of the share in 2025, with the promising ongoing growth, with the modernizations in peptide design featuring the potential of stapling and backbone cyclization. This is an aid to the blood-brain barrier and brings balance to metabolism.
• Cardiovascular Disorders - The cardiovascular disorders segment held 10% of the share in 2025, with the steady upcoming growth in the segment due to modernizations in drug delivery. The peptide delivery technologies and formulation is a big strength to the segmental market growth.

North America Peptide Therapeutics Market Share, By Route of Administration Outlook, 2025 (%)

• Parenteral Route -The parenteral route segment held 82% of the share in 2025, with consistent growth planning of sustained-release injectable technologies utilization. The convincing bioavailability strength brings efficacy and effectiveness. While the green signal to parenteral methods is encouraging, the segmental market for higher innovations.
• Oral Route -The oral route segment acquired 8% of the share in 2025, with the intelligent growth pathway focusing on the chronic conditions requirement list for therapeutics, while the oral alternative is much appreciated. The enteric coatings and encapsulation healthcare creativity are enhancing the bioavailability.
• Pulmonary - The pulmonary segment held 5% of the share in 2025, with the steady growth cycle aiming at the number of chronic illnesses to serve the demand for inhalation-related peptide drugs. The nebulizers and DPIs are a popular delivery boon to the patients and the segmental market as well.
• Mucosal -The mucosal segment secured 4% of the share in 2025, with the effective growth in the running strategies featuring the non-invasive delivery for both oral and mucosal routes. While the permeation enhancers and nanocarriers are a shield to peptides, promoting the potential value of the novel drug delivery systems in the segment.

North America Peptide Therapeutics Market Share, By Synthesis Technology Outlook, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS) -The SPPS segment covered 55% of the share in 2025, with the ongoing growth covering green chemistry contribution, highlighting the mitigating and recycling reagent protocols. The CDMO's strength is accelerating the confidence of the GLP-1 peptide to bolster the segmental market.
• Recombinant DNA Technology -The segment held 25% of the share in 2025, with the steady growth reaching the tech line of solution to support the creation of critical peptides. While the metabolic condition helps the segment prove its potential value in the market.
• Hybrid -The hybrid segment acquired 10% of the share in 2025, with the upcoming growth to concentrate on industry demand due to the rising diabetes and obesity stress, encouraging manufacturers to switch to the hybrid solution.
• Liquid-Phase Peptide Synthesis (LPPS) - The LPPS segment held 7% of the share in 2025, with steady growth to be navigated with the greener approaches to the segmental advancement. The breakthrough therapy is paving the way for more expansion into the segmental market.

North America Peptide Therapeutics Market Share, By Type of Manufacturers Outlook, 2025 (%)

• Outsourced - The outsourced segment held 58% of the share in 2025, with the smart growth expertise for the critical synthesis. The pharmaceuticals benefit from the outsourcing since their capital expenditures are trimmed to further elevate clinical timelines.
• Inhouse - The inhouse segment acquired 42% of the share with a strong base of favorable infrastructure that strengthens the internal facilities, also favoring the supply chains as well. The oncology therapies bring consistent profit to the in-house production settings.

Top Companies in the North America Peptide Therapeutics Market

• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Novo Nordisk A/S
• GSK plc
• Ironwood Pharmaceuticals, Inc.
• Radius Health, Inc.
• Ipsen Pharma

Segments Covered in the Report

By Type

• Innovative
• Generic

By Application

• Metabolic Disorders
• Cancer
• Neurological Disorders
• Gastrointestinal Disorders
• Cardiovascular Disorders
• Pain
• Infectious Disease
• Renal Disorders
• Dermatological Disorders
• Respiratory Disorders
• Others

By Route of Administration

• Parenteral Route
• Oral Route
• Mucosal
• Pulmonary
• Others

By Synthesis Technology

• Recombinant DNA Technology
• Solid-Phase Peptide Synthesis (SPPS)
• Hybrid
• Liquid-Phase Peptide Synthesis (LPPS)
• Others

By Type of Manufacturers

• Inhouse
• Outsourced